Immuno-oncology in urothelial carcinoma: who or what will ultimately sit on the iron throne?

Immunotherapy. 2017 Sep;9(12):951-954. doi: 10.2217/imt-2017-0109.
No abstract available

Keywords: IDO1; adoptive T-cell therapy; bladder cancer; checkpoint inhibitors; immuno-oncology.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antineoplastic Agents, Immunological / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors
  • Carcinoma / therapy*
  • Clinical Trials as Topic
  • Humans
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • T-Lymphocytes / transplantation
  • Urinary Bladder Neoplasms / therapy*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • CD274 protein, human
  • IDO1 protein, human
  • Indoleamine-Pyrrole 2,3,-Dioxygenase
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor